- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 253
Tiger Brokers catches $104m in IPO
The Xiaomi-backed online brokerage floated above its range while its other corporate investor, International Brokers, bought more than $13m of shares.
Mar 21, 2019Pine Labs to swipe Qwikcilver for $110m
The gift card services provider is set be acquired by Pine Labs in a $110m deal, after raising more than $21m from investors including Amazon and Sistema.
Mar 21, 2019Innogy finds exit hatch at Airec
Innogy's corporate venturing unit has offloaded its stake in heat exchanger producer Airec to Alfa Laval and Sveper Heat Transfer.
Mar 21, 2019Stryker gathers OrthoSpace in $220m deal
Smith & Nephew and Johnson & Johnson have exited the shoulder implant developer in an all-cash acquisition by Stryker that could reach $220m.
Mar 20, 2019Wanda and Vortex to vacate stage
Embattled commercialisation firm NetScientific is closing two medical diagnostics spinouts from UCLA after both failed to attract external funding.
Mar 19, 201936Kr seeks lowdown in $100m IPO
36Kr Media is considering an initial public offering in the US that would be sized at about $100m, providing exits for Baidu Video and Focus Media Information Technology.
Mar 19, 2019Alcon sees way to $285m PowerVision acquisition
Alcon acquired the intraocular lens developer in a $285m deal that follows $106m in funding from investors including its parent company Novartis as well as Johnson & Johnson and Medtronic.
Mar 19, 2019Minute Media takes on The Big Lead
Minute Media has purchased the sports blogging and media platform for an undisclosed amount, allowing Gannett to exit.
Mar 19, 2019Lyft accelerates towards $2.1bn IPO target
Lyft has set the range for an IPO that would allow Alphabet, Rakuten, GM, Jaguar Land Rover, Alibaba, Didi Chuxing, Magna and Icahn Enterprises to exit, valuing it at up to $22.9bn.
Mar 18, 2019NervGen Pharma holds nerve for $7.5m IPO
CWRU-licensed NervGen Pharma floated at the top of its range on the TSX Venture Exchange, with the proceeds earmarked to push its lead candidate for spinal cord injury into the clinic.
Mar 18, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


